Abstracts - PAGE Meeting (Population Approach Group Europe)

Abstracts (24)

I-060Zhendong Chen

A joint pharmacometric model of iohexol and creatinine administered through a meat meal to assess GFR and renal OCT2/MATE activity

Wednesday 10:30-12:00

I-087Gerbert Coen De Waard

Unraveling the PK of target site cefuroxime exposure in prosthetic joint infection patients: a population PK analysis

Wednesday 10:30-12:00

I-097Nada Dia

Optimizing vancomycin dosing in older patients: predictive performance of pharmacometrics models

Wednesday 10:30-12:00

I-104Thomas Duflot

Population PK/PD modeling of levobupivacaine and ropivacaine for motor block in spinal anesthesia

Wednesday 10:30-12:00

II-012Peggy Gandia

Population pharmacokinetic modelling of amoxicillin concentrations in human breast milk – a contribution from the ConcePTION project

Wednesday 15:30-17:00

II-081Marian Klose

A Bayesian-NLME approach identifies patients at risk of delayed MTX elimination if informative TDM data is provided

Wednesday 15:30-17:00

II-085S.F. Koopman

Relationship between factor IX activity levels and bleeding in patients with haemophilia B on prophylaxis with an extended half-life factor IX concentrate (rIX-FP): A repeated time-to-event analysis.

Wednesday 15:30-17:00

II-100Félicien Le Louedec

Model-averaging, but not flattened priors, benefitted to the model-informed precision dosing of oral kinase inhibitors in oncology

Wednesday 15:30-17:00

II-111Dr. Xia Li

Nipocalimab Effect on IgG Subclasses in Patients with Generalized Myasthenia Gravis (gMG)

Wednesday 15:30-17:00

III-023Dr. Lara Marques

Improving Individualized Salbutamol Treatment: A Population Pharmacokinetic Model for Oral Salbutamol in Virtual Patients

Thursday 9:50-11:45

III-026Loes Maton

A review on the role of extrapolation as basis for paediatric marketing authorization applications of medicines in the EU

Thursday 9:50-11:45

III-032Danica Michalickova

Pharmacokinetic optimization of valganciclovir and ganciclovir therapy in lung transplant recipients

Thursday 9:50-11:45

III-052Van Dong Nguyen

Exploring the impact of clinical covariates on predictive performance of vancomycin population pharmacokinetic modeling in patients receiving high flux intermittent hemodialysis

Thursday 9:50-11:45

III-097Ousama Rachid

Mechanistic Insights in the Ketamine Pharmacokinetics after Intranasal Administration in the Pediatric Population: Bridging Model Validation to Clinical Application

Thursday 9:50-11:45

IV-020Myra Skerlep

Model-Based Approach for a New Prolonged-Release (PR) Formulation of Ivabradine: PK and PKPD Assessment to Support Bioequivalence

Thursday 15:00-16:45

IV-026Felix Stader

Physiologically based pharmacokinetic modelling to predict antibody exposure in patients with hepatic impairment

Thursday 15:00-16:45

IV-029Marylise Sterlé

Linking Abemaciclib Exposure and Early Toxicity in HR+/HER2- Breast Cancer Patients: Insights from Real-World Data

Thursday 15:00-16:45

IV-037Zhiyuan Tan

Advancing 5-FU precision dosing: external PK model evaluation, generic PK model development, novel limited sampling strategies and fit-for-use shiny application

Thursday 15:00-16:45

IV-043Gilles Tiraboschi

Population PK/PD Modeling to Predict Efficacy of Extended Dosing of Amlitelimab in Moderate-to-Severe Atopic Dermatitis Patients

Thursday 15:00-16:45

IV-044Dominic Tong

Evaluation of population pharmacokinetic model predictive performance in adults on hemodialysis treated with vancomycin

Thursday 15:00-16:45

IV-077Alina Volkova

Model-based meta-analysis of targeted therapies in systemic lupus erythematosus and its manifestations

Thursday 15:00-16:45

IV-096Nuo Xu

Population pharmacokinetics of total and unbound concentrations of intravenous caspofungin in Chinese critically ill pediatric patients

Thursday 15:00-16:45

IV-097Ling Xue

Dynamic interaction modeling of adalimumab and anti-drug antibodies in ankylosing spondylitis

Thursday 15:00-16:45

IV-113Xiao Zhu

A Semi-Mechanistic Population Pharmacokinetic Model of Linezolid in ICU Patients with Renal Impairment: Optimizing Dosing for Effective Urinary Tract Infections Treatment

Thursday 15:00-16:45